Updates on Three FTSE 100 Stocks – Polymetal International Plc, Evraz Plc and AstraZeneca Plc

POLY Production Results

On 24^th October 2019, the company announced its production update for the third quarter ended 30^th September 2019. The company highlighted that in the third quarter, gold equivalent production increased by 7 per cent year on year to 476 Koz. driven by Kyzyl where the gold equivalent production was at 94 Koz. Quarterly gold production increased by 13 per cent while silver production reduced by 20 per cent after disposal of assets in 2018 and grade decline at Dukat, which was planned. Gold equivalent production for the first nine months of 2019 (year to date) displayed an increase of 16 per cent to 1,232 Koz. The company also reported that it anticipates surpassing its full-year production guidance of 1,550 Koz by approximately 50 Koz. The company also highlighted that revenue grew by 43 per cent to US $656 million following higher sales volumes and higher prices as well. The cyclical gap between production and sales has been completely closed.

POLY Share Performance

On 24^th October 2019, at 12:28 PM GMT, while writing, Polymetal International Plc’s stock traded at GBX 1201.10 per share, an increase of 1.40 per cent or GBX 16.60 per share in comparison with the previous day’s closing price which was reported at GBX 1184.5 per share. At the current market price, the company’s stock was trading 1.08 per cent below its 52-week high price of GBX 1214.19 per share, which the company’s stock hit on September 04, 2019. The company’s 52-week low price is of GBX 697.60 per share, which it hit on November 12, 2018. The company’s Market Capitalisation was around GBP 5.569 billion.

By the time of writing, 372,850 stocks of the company had been traded for the day. The average volume of trading per day for last one year has been 1.43 million. The stock has gained 65.44 per cent in the last one year from the price of GBX 726.00 per share.

The Beta of the stock has been reported to be at 0.0949, from which it can be inferred that the stock’s price movement, is less volatile as compared to the movement of the comparative benchmark index.

Evraz Plc

Evraz Plc (EVR) is a Moscow, Russia based mining company, that is engaged in the exploration, as well as manufacturing of Steel, Iron ore, Coal and various products and applications of these metals and minerals. The company’s most significant business segment is the mining and production of steel-based products. The company’s steel assets include Evraz ZSMK, which is the easternmost asset in Russia which has been dedicated to long products such as low alloy steel, rebar and wire rods, and shaped steel. This asset led to a production of 6 million tonnes of steel as well as 3.4 million tonnes of marketable concrete in the year 2018, Evraz NTMK, which mainly engages in the development of railway transport products and was responsible for the production of 4.1 million tonnes of steel and 4 million tonnes of steel products in the year 2018 and Evraz KGOK, which is one of the five largest ore mining spaces in Russia, with production of 3.5 million tonnes of Sinter as well as 6.5 million tonnes of pellets reported in the year 2018. This space has a capacity of 55 million tonnes of Iron ore per year.

EVR Latest News

On 18^th October 2019, through a press release, the company announced the acquisition of pilot plant and technology for tailings processing. As per the press release, JCS EVRAZ Vanady Tula, a subsidiary of Evraz Plc, acquired the pilot plant and technology for EVRAZ Kachkanarsky Ore Mining and Processing Plant tailing processing, which is another subsidiary of the group from LLC Rock Capital Partners for Russian Ruble 249.132 million which roughly translates to US $3.8 million. The acquisition consideration has been confirmed by an independent estimation report prepared by LLC American Appraisal. As per the announcement, this will allow the company to enjoy a positive economic effect from more than 1.5 billion of its tailings being dumped and going to waste amounting around 80 per cent of the total produce.

EVR Share Performance

On 24^th October 2019, at 12:52 PM GMT, while writing, Evraz Plc’s stock traded at GBX 385.30 per share, a decrease of 1.96 per cent or GBX 7.70 per share in comparison with the previous day’s closing price which was reported at GBX 393.00 per share. The company’s share price set a 52-week low on October 21, 2019, trading, when it reached GBX 373.38 per share. The company’s 52-week high price is of GBX 710.20 per share, which it hit on June 17, 2019. The company’s Market Capitalisation is GBP 5.706 billion.

By the time of writing, 673,690 stocks of the company had been traded for the day. The average volume of trading per day for last one year has been 2.95 million. The stock has lost 26.10 per cent in the last one year from the price of GBX 521.40 per share.

The Beta of the stock has been reported to be at 2.1237, from which it can be inferred that the stock’s price movement, approximately is twice as more volatile as compared to the movement of the comparative benchmark index.

AstraZeneca Plc

AstraZeneca Plc (AZN) is a pharmaceutical and biotechnology company based in Cambridge, the United Kingdom. The company engages in the research and development, production and later marketing and selling of products in the therapy areas of Oncology, Cardiovascular & Metabolic Diseases and Respiratory. Some of the other treatment areas that the company focuses on are Inflammation and Autoimmunity, Infection and Vaccines, Neuroscience and Eosinophil driven diseases as well as gastrointestinal issues.

AZN Financial Performance (Year to date and third-quarter results)

On 24^th October 2019, the company announced its results for the third quarter and nine months ended 30^th September 2019. The company reported the product sales increased by 13 per cent year on year for the nine months ended 30^th September 2019 at US $17.315 billion. The third-quarter product sales were reported at US $6.132 billion, which was an increase of 16 per cent year on year. This led to year on year total revenue growth of 20 per cent in the third quarter of 2019 at US $6.406 billion and a 13 per cent year on year increase in the total revenue for the Year to date at US $17.720 billion. The company reported Other Operating Income and Expense to have declined by 32 per cent year on year from the year to date at US $1.041 billion and Core Other Operating Income and Expense to have declined by 7 per cent year on year to US $1.060 billion. The company reported earnings per share at US $0.79 per share for the year to date, based on a weighted-average number of shares of 1.297 billion, reflecting a decline of 11 per cent year on year. The company has been able to achieve one new molecular entity approval in the trailing quarter.

AZN Share Performance

On 24^th October 2019, at 01:25 PM GMT, while writing, AstraZeneca Plc’s stock traded at GBX 7182.50 per share, an increase of 3.81 per cent or GBX 263.58 per share in comparison with the previous day’s closing price which was reported at GBX 6919.00 per share. At the current market price, the company’s stock was trading 12.70 per cent below its 52-week high price of GBX 8227.88 per share, which the company’s stock hit on October 07, 2019. The company’s 52-week low price is of GBX 5312.00 per share, which it hit on January 28, 2019. The company’s Market Capitalisation was around GBP 90.769 billion.

By the time of writing, 1.21 million stocks of the company had been traded for the day. The average volume of trading per day for last one year has been 1.77 million. The stock has gained 21.10 per cent in the last one year from the price of GBX 5931.00 per share.

The Beta of the stock has been reported to be at 0.8562, from which it can be inferred that the stock’s price movement, is less volatile as compared to the movement of the comparative benchmark index.